Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics Forms BiSpecifics Collaboration with Brii Bio

publication date: Dec 10, 2018

WuXi Biologics will collaborate with Brii Biosciences, a China-US startup, to discover novel bispecific targets for infectious diseases and other immunologic disorders. WuXi will employ its WuXiBody™ technology to discover the bispecific antibodies, and it will be Brii Bio's exclusive development and manufacturing partner for any novel bispecific antibodies. WuXi said its platform develops candidates that break through CMC barriers usually encountered by bispecifics and will speed up development by 6-18 months. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.